Skip to main content
Erschienen in: Rheumatology International 7/2019

08.05.2019 | Public Health

Does YouTube provide high quality information? Assessment of secukinumab videos

verfasst von: Burhan Fatih Kocyigit, Mazlum Serdar Akaltun

Erschienen in: Rheumatology International | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

The Internet is a widely used source for obtaining health-related information. With the widespread use of the Internet, access to information has become easier. YouTube is one of the major sources for health-related videos globally. YouTube provides a wide range of health-related information, but there are doubts about its quality and reliability. Therefore, we aimed to assess the quality of the most viewed secukinumab videos on YouTube. This is a descriptive study. A total of 180 secukinumab videos returned by the YouTube search engine (http://​www.​youtube.​com) in response to a keywords query were evaluated in the study. The Global Quality Scale (GQS) was used to assess educational quality, and three groups were created: high quality, intermediate quality, and low quality. Video parameters were compared among the quality groups. After applying the exclusion criteria, 53 videos were analyzed; 18 (34%) videos were in the high-quality group, 17 (32%) were in the intermediate-quality group, and 18 (34%) were in the low-quality group. No significant difference was detected in terms of the number of views, likes, dislikes, and comments per day between the groups (p > 0.05). YouTube has a mixed structure of high, intermediate, and low-quality videos. The number of views, likes, dislikes, and comments per day should not be accepted as an indicator of quality for YouTube videos. In addition, patients should consider the importance of sources when obtaining online health-related information.
Literatur
1.
Zurück zum Zitat Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewé R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S, FUTURE 1 Study Group (2015) Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 373:1329–1339. https://doi.org/10.1056/NEJMoa1412679 CrossRefPubMed Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewé R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S, FUTURE 1 Study Group (2015) Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 373:1329–1339. https://​doi.​org/​10.​1056/​NEJMoa1412679 CrossRefPubMed
2.
Zurück zum Zitat Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C, ERASURE Study Group; FIXTURE Study Group (2014) Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med 371:326–338. https://doi.org/10.1056/NEJMoa1314258 CrossRefPubMed Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C, ERASURE Study Group; FIXTURE Study Group (2014) Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med 371:326–338. https://​doi.​org/​10.​1056/​NEJMoa1314258 CrossRefPubMed
3.
Zurück zum Zitat Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewé R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachat A, Bek S, Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382:1705–1713. https://doi.org/10.1016/S0140-6736(13)61134-4 CrossRefPubMed Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewé R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachat A, Bek S, Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382:1705–1713. https://​doi.​org/​10.​1016/​S0140-6736(13)61134-4 CrossRefPubMed
9.
Zurück zum Zitat Bernard A, Langille M, Hughes S, Rose C, Leddin D, Veldhuyzen van Zanten S (2007) A systematic review of patient inflammatory bowel disease information resources on the world wide web. Am J Gastroenterol 102:2070–2077CrossRefPubMed Bernard A, Langille M, Hughes S, Rose C, Leddin D, Veldhuyzen van Zanten S (2007) A systematic review of patient inflammatory bowel disease information resources on the world wide web. Am J Gastroenterol 102:2070–2077CrossRefPubMed
10.
Zurück zum Zitat Charnock D, Shepperd S, Needham G, Gann R (1999) DISCERN: an instrument for judging the quality of written consumer health information on treatment choices. J Epidemiol Community Health 53:105–111CrossRefPubMedPubMedCentral Charnock D, Shepperd S, Needham G, Gann R (1999) DISCERN: an instrument for judging the quality of written consumer health information on treatment choices. J Epidemiol Community Health 53:105–111CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Erdem MN, Karaca S (2018) Evaluating the accuracy and quality of the information in kyphosis videos shared on YouTube. Spine (Phila Pa 1976) 43:E1334–E1339CrossRef Erdem MN, Karaca S (2018) Evaluating the accuracy and quality of the information in kyphosis videos shared on YouTube. Spine (Phila Pa 1976) 43:E1334–E1339CrossRef
Metadaten
Titel
Does YouTube provide high quality information? Assessment of secukinumab videos
verfasst von
Burhan Fatih Kocyigit
Mazlum Serdar Akaltun
Publikationsdatum
08.05.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 7/2019
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-019-04322-8

Weitere Artikel der Ausgabe 7/2019

Rheumatology International 7/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.